RecruitingNCT07609394

Duchenne Electronic Health Record Study

Duchenne Outcomes Research Interchange Data Enrichment Through EHR Extraction


Sponsor

The Duchenne Registry

Enrollment

2,500 participants

Start Date

Dec 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to collect retrospective and prospective, long-term data of patients with dystrophinopathy (including Duchenne, Becker, and female carriers) through electronic transfer. At select clinics across the United States, electronic health record (EHR) data from consented patients will be pushed into PPMD's Duchenne Outcomes Research Interchange (the Interchange), where the EHR data can be combined with patient-reported data from The Duchenne Registry. By combining this data in a central hub, we will gain a more complete picture of Duchenne and Becker muscular dystrophy, allowing researchers and clinicians to develop treatments faster and to improve and refine the standards of care for Duchenne and Becker. The ultimate goal is to optimize function, quality of life, and survival of Duchenne and Becker patients. EHR data collected will be fully identifiable retrospective data for core clinical data elements going back ten years (as available) from the date of consent; going back one year for retrospective clinical notes from the date of consent; and prospectively collecting both core clinical data elements and clinical notes. Information collected will align with the FHIR U.S. core data elements, also known as the Common Clinical Data Set. PPMD partnered with Prometheus Research (an IQVIA company), an industry leader in health data informatics, to launch both the EHR Study and the Interchange. All data is stored securely and in accordance with strict industry standards and patient privacy laws. Participation in the EHR data extraction is voluntary, and a patient can withdraw consent at any time.


Eligibility

Inclusion Criteria3

  • Duchenne or Becker muscular dystrophy or female carrier
  • Must be a patient at an institution that has an established EHR integration set up with PPMD's Interchange
  • Must provide consent to have their EHR data pushed to the Interchange and linked to existing Registry data, if applicable

Exclusion Criteria3

  • Individuals with other forms of muscular dystrophy
  • Individuals who do not provide consent
  • Individuals with Duchenne/Becker who have severe mobility/strength issues need to provide consent and participate with assistance from a caregiver. Adults with communication impairments and/or intellectual disabilities (considered the "decisionally impaired" group for purposes of this study) will be able to consent with the assistance of the adults who are designated Legally Authorized Representative (LAR). Without assistance, this group will be excluded from participation because the consent process.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservational study with patients who may be treated with various disease-modifying therapies

Patients may be on any combination of therapies to participate, including FDA-approved therapies (corticosteroids, exon skipping therapy, gene therapy) or therapies in clinical trial.


Locations(10)

Arkansas Children's Hospital

Little Rock, Arkansas, United States

UC Davis Health

Sacramento, California, United States

Children's Hospital Colorado

Aurora, Colorado, United States

Yale Children's Hospital

New Haven, Connecticut, United States

Children's National Medical Center

Washington D.C., District of Columbia, United States

University of Iowa Health Care

Iowa City, Iowa, United States

Duke University Medical Center

Durham, North Carolina, United States

UT Southwestern Medical Center

Dallas, Texas, United States

Primary Children's Hospital

Salt Lake City, Utah, United States

University of Utah Health

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07609394


Related Trials